Home Neuronal Signaling P2 Receptor antagonist Minodronic acid

research use only

Minodronic acid P2 Receptor antagonist

Cat.No.S5057

Minodronic acid (YM529, ONO-5920) is a third-generation nitrogen-cotaining bisphosphonate that is used for the treatment of osteoporosis. This compound is an aminobisphosphonate that is a selective antagonist of purinergic P2X2/3 receptors involved in pain.
Minodronic acid P2 Receptor antagonist Chemical Structure

Chemical Structure

Molecular Weight: 322.15

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S505701 0.5MNAOH]3.06 mg/mL]false]DMSO]0.001 mg/mL]false]Water]Insoluble]false Purity: 99.68%
99.68

Chemical Information, Storage & Stability

Molecular Weight 322.15 Formula

C9H12N2O7P2

 Storage (From the date of receipt)
CAS No. 180064-38-4 -- Storage of Stock Solutions

Synonyms YM529, ONO-5920 Smiles C1=CC2=NC=C(N2C=C1)CC(O)(P(=O)(O)O)P(=O)(O)O

Solubility

In vitro
Batch:

0.5MNAOH : 3.06 mg/mL

DMSO : 0.001 mg/mL (0.0 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00965978 Completed
Osteoporosis|Osteoporosis Postmenopausal|Bone Diseases
Astellas Pharma Inc|Ono Pharma USA Inc
 July 2009 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map